FDA approves Purdue's controversial OxyContin for kids aged 11 to 16

Purdue Pharma now has FDA permission to market highly controversial opioid painkiller OxyContin to an even younger population. Late last week, the agency green-lighted the drug in patients aged 11 to 16 who haven't benefited enough from alternative therapies. The warnings and precautions for pediatric patients are the same as those for adults, the FDA said. More

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.